Nimenrix Dosing for Infants Starting Before 6 Months of Age
For infants starting Nimenrix (MenACWY-TT) before 6 months of age, a 4-dose primary series is required at 2,4,6, and 12 months of age.
Age-Specific Dosing Schedule
Starting at 2 Months of Age
- Administer 4 doses at 2,4,6, and 12 months 1, 2
- This is the standard schedule for high-risk infants beginning vaccination at the earliest approved age 3
Starting at 3-6 Months of Age
- Follow a catch-up schedule with doses at 8-week intervals until the infant reaches ≥7 months of age 3, 2
- Then administer an additional dose at age ≥7 months, followed by a final dose at least 12 weeks later and after the first birthday 1, 3
- This ensures adequate immune response despite the delayed start 2
Starting at 7-23 Months of Age
- Administer only 2 doses total: the second dose must be given at least 12 weeks after the first dose and after the first birthday 1, 3, 2
- This reduced schedule is appropriate for older infants who have more mature immune systems 3
Important Clinical Considerations
High-Risk Populations Requiring Early Vaccination
Nimenrix should be started before 6 months in infants with:
- Persistent complement component deficiencies (C3, C5-C9, properdin, factor D, factor H) 1, 3
- Functional or anatomic asplenia 1, 3
- Travel to or residence in hyperendemic/epidemic meningococcal disease areas 3
- Exposure during community outbreaks 1, 2
Vaccine Interference Precautions
- For infants with asplenia or HIV infection, delay MenACWY-D (not Nimenrix/MenACWY-TT) until after age 2 years to avoid interference with pneumococcal conjugate vaccine (PCV13) 1, 2
- Nimenrix (MenACWY-TT) can be given at any age ≥6 weeks without this restriction, making it preferable in these high-risk populations 3, 4
Booster Dose Requirements
- For children vaccinated before age 7 years who remain at increased risk: give first booster 3 years after primary series completion, then every 5 years thereafter 1, 3
- For children vaccinated at age ≥7 years who remain at increased risk: give booster every 5 years 3
Recent Evidence Supporting Flexibility
A 2025 phase 3B study demonstrated that a simplified 1+1 schedule (single dose at 3 months plus booster at 12 months) achieved 100% seroprotection rates across all serogroups after the booster dose, with robust anamnestic responses 5. However, this alternative schedule is not yet incorporated into official guidelines, and the standard 4-dose series remains the recommended approach for infants starting before 6 months 1, 3.